Four months ago, the FDA placed a clinical hold on Celyad’s CAR-T trial for colorectal cancer after two patients died during the study. Regulators have now lifted the hold, allowing the Belgian company’s trial to set sail once again.

Celyad’s voluntary pause didn’t last long.

The biotech put out word after the market closed Monday that the FDA has swiftly followed up the news of 2 patient deaths and an announced pause with a clinical hold, shifting control over the trial halt to federal regulators.

On the corporate front Astellas continued to buy, while Qiagen decided that it was not, after all, up for sale.

Nextcure’s Society for Immunotherapy of Cancer presentation gave investors little reason for cheer, but there's better news for Pieris, Celyad and Nektar.

Biotech stocks headed south last week, reversing decent gains made in the previous week. Unfavorable FDA decisions, botched trials and weaker broader market sentiment all weighed down on the sector.

Here are the key catalysts of the unfolding week.